Economics
A Breakthrough Cancer Drug Has Been Approved. Now Comes the Battle Over the Price
- Drugmaker introduces Kymriah at 320,000 euros in Germany
- CAR-T cancer treatment was approved in Europe last month
This article is for subscribers only.
Novartis AG’s breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its hefty cost.
In Germany, Novartis has set a price of 320,000 euros ($371,000) that’s now subject to negotiation with authorities, Pascal Touchon, head of the drugmaker’s cell and gene therapy business, said in an interview. That’s the list price to treat a form of childhood leukemia and a type of lymphoma in adults. Similar discussions are playing out elsewhere in Europe.